Reference Materials for Pharmacogenetics
| TPMT and NUDT15 | GeT-RM used a variety of methods to characterize DNA from 30 Coriell cell lines to create a panel of reference materials for TMPT and NUDT15 (J Mol Diag 2022 24:1079-1088). The data from each method and consensus diplotypes for each sample can be viewed here. The assays used and alleles tested can be viewed here. |
| CYP2C8, CYP2C9 and CYP2C19 (Next Generation sequencing) | GeT-RM used targeted and whole genome sequencing analysis to recharacterize 137 DNA samples that were previously characterized using a variety of targeted genotyping assays to identify star allele diplotypes for CYP2C8, CYP2C9, and CYP2C19. The data from each test method and consensus diplotypes for each sample can be viewed here |
| VKORC1 warfarin resistant variants, CYP2C9*13, CYP2C10*35, CYP2C cluster, GGCX | GeT-RM characterized 18 cell line DNA samples to create reference materials containing pharmacogenetic alleles classified as “Tier 2” by the Association for Molecular Pathology PGx Work Group (J. Mol Diag 2021 23:952-958). A subscription to the journal is required to view the article until 2022; after that it will be available to the public. The data from each test method and consensus diplotypes for each sample can be viewed here Tier 2 GeT-RM website table |
| CYP2D6 | The CYP2D6 gene in DNA from 179 cell lines including rare and/or difficult to analyze alleles and/or diplotypes were characterized by the GeT-RM using a variety of methods (J Mol Diag 2019 21:1034-1052). The data from each test method and consensus diplotypes for each sample, assays used, and alleles tested can be viewed here. |
| CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, DPYD, GSTM1, GSTP1, GSTT1, NAT1, NAT2, SLC15A2, SLC22A2, SLCO1B1, SLCO2B1, TPMT, UGT1A1, UGT2B7, UGT2B15, UGT2B17, VKORC1 | DNA from 137 cell lines was characterized by the GeT-RM for 28 PGx genes using a variety of methods. (J Mol Diag 2016 Jan:18(1): 109-23). The assays used and alleles tested can be viewed with this link. Consensus genotype data and data by platform are presented in the following tables for all 28 loci together and for each of the 28 loci individually:
|
| CYP2D6, CYP2C19, CYP2C9, VKORC1 and UGT1A1 | DNA from 107 cell lines was characterized for CYP2D6, CYP2C19, CYP2C9, VKORC1 and UGT1A1 by the GeT-RM using a variety of methods. (J Mol Diag 2010 12(6):835-846). The assays used and alleles tested in this study can be viewed with this link. (106 of these samples were also characterized by GeT-RM for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPA1, and DPB1, see Inherited Genetic Reference Material and HLA page. (J Mol Diag 2018, 20: 703-715) Data are presented in the following tables for all 5 loci together and for each of the 5 loci individually: |
Additional GeT-RM Data
| ABCC2, ABCC4, CDA, CYP1B1, CYP2A13, CYP2F1, CYP2J2, CYP2S1, CYP3A7, CYP3A43, CYP4B1, CYP19A1, FMO2, G6PD, IFNL3, ITPA, PTGIS, SULT1A1, TBXAS1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10 | These are additional data for 137 DNA samples obtained during the GeT-RM PGx characterization study (J Mol Diag 2016 Jan:18(1) 109-23). Data are from one assay only. The assay used to characterize each gene is indicated. |
| CYP4F2, EPHX1, ABCB1, HLAB, KIF6, CYP3A4, CYP3A5, TPMT, DPD. | These are additional data about 107 DNA samples obtained during the GeT-RM PGx characterization study (J Mol Diag 2010 12(6):835-846). Data are from only one laboratory. |
Send inquiries about information on this website through this page: Contact CDC-INFO. If you need help reading any of the data tables in the PDFs and Excel spreadsheets on this page, please use the phrase “GeT-RM Data Tables: Assistance with reading” in the subject line of your email.